Why the study?
Does pentasaccharide improve coronary patency and reduce reocclusion compared to unfractionated heparin in patients with STEMI receiving aspirin and alteplase?
Does pentasaccharide improve coronary patency and reduce reocclusion compared to unfractionated heparin in patients with STEMI receiving aspirin and alteplase?
Pentasaccharide as an adjunct to alteplase in STEMI is safe and as effective as unfractionated heparin for initial coronary patency, with a trend toward reduced subsequent reocclusion.
No takes yet. Share an insight, caveat, or question.
Comparable initial patency supports pentasaccharide as heparin alternative in STEMI; extends evidence with trends toward less reocclusion.
Patrick Coussement (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: